ArticleMicrobial biotechnology2026
Lactobacillus paragasseri LG-1 Alleviates Urticaria-Like Symptoms in Mice via Modulation of Gut Microbiota, Hypoxanthine and Uric Acid.
Article in Microbial biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mechanisms of Gut Microbiota-Derived Metabolites in Treating Hyperuricemia: Natural Products as Interventions.Molecules (Basel, Switzerland) · 2026Review
- Lactobacillus paragasseri LG-1 Alleviates Urticaria-Like Symptoms in Mice via Modulation of Gut Microbiota, Hypoxanthine and Uric Acid.Microbial biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Chronic Spontaneous Urticaria (CSU) is an immunoinflammatory disorder with complex pathogenesis. Emerging evidence implicates that gut microbiota dysbiosis plays a pivotal role in this pathological network. Integrated 16S rRNA sequencing and untargeted metabolomics revealed distinct CSU-associated signatures, including significant reductions in Lactobacillus abundance and elevated serum uric acid (UA) and hypoxanthine levels. Functional screening identified Lactobacillus paragasseri LG-1 from breast milk as a potent purine-metabolising strain, demonstrating significant hypoxanthine and UA degradation in vitro. In an ovalbumin (OVA)-induced urticaria murine model, LG-1 administration demonstrated marked reductions in serum UA and hypoxanthine concentrations, alleviated clinical manifestations, and suppressed inflammation via TLR4-NF-κB pathway inhibition. Moreover, it modulated gut microbial composition by promoting Lactobacillus proliferation while restraining pathogenic bacteria. These findings collectively established that LG-1 exerted dual therapeutic effects through uric acid/hypoxanthine degradation and microbiome remodelling. Our study provides compelling evidence for microbiome-targeted strategies in CSU management, highlighting LG-1 as a promising therapeutic candidate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.